Holen Sie sich die Stockscreener-App
90.74
2.12%
-1.97
Handel nachbörslich:
91.36
0.62
+0.68%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$92.71
Offen:
$93.29
24-Stunden-Volumen:
9.60M
Relative Volume:
0.75
Marktkapitalisierung:
$158.05B
Einnahmen:
$45.13B
Nettoeinkommen (Verlust:
$6.28B
KGV:
25.28
EPS:
3.5895
Netto-Cashflow:
$7.38B
1W Leistung:
+0.23%
1M Leistung:
+6.00%
6M Leistung:
-27.58%
1J Leistung:
-33.28%
1-Tages-Spanne:
$90.61
$93.29
1-Wochen-Bereich:
$90.28
$95.21
52-Wochen-Spanne:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
90.74 | 163.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
314.84 | 127.55B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.23 | 103.66B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
42.68 | 65.74B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.46 | 52.27B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
US criminal probe into Abbott infant-formula plant closed - Global Food Industry News
Trump Admin Stopped Criminal Charges Against Abbott Nutrition for Infant Formula Illnesses - Food Safety Magazine
Abbott Laboratories earnings calendar, shares in focus on the NYSE - AD HOC NEWS
Abbott Laboratories was investigated for poisoning babies. After a $500,000 donation, Trump let them off the hook. - More Perfect Union | Substack
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo! Finance Canada
Form 4 Abbott Laboratories For: 29 June By Investing.com - Investing.com Canada
Abbott (ABT) EVP Cushman disposes 560 shares for tax withholding, retains 38,013 - Stock Titan
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Coca Cola Stock And 2 Defensive Picks For Steady Dividends - simplywall.st
MDL Sought for Abbott Spinal Cord Stimulator Lawsuits - AboutLawsuits.com
How Abbott's Largest Segment Is Preparing for the Next Growth Phase - TradingView
Abbott Laboratories dropped from Russell Top 50, shares hold above Tradegate level - AD HOC NEWS
Abbott Laboratories (ABT) Criminal Probe Closed by Justice Depar - GuruFocus
U.S. Justice Department Closes Criminal Probe into Abbott Laboratories - Intellectia AI
DOJ dropped Abbott baby formula criminal probe despite pile of evidence: WSJ (ABT:NYSE) - Seeking Alpha
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports - Reuters
Exclusive | The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case. - WSJ
In a Volatile Market, This Dividend Growth Stock Is Worth Every Penny of $1,000 - The Motley Fool
Enterprise value to revenue forward of Abbott Laboratories – NYSE:ABT - TradingView
Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market - Kavout | AI
Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children’s Growth - Insider Monkey
Brain Implants Market Size to Reach USD 18.39 Billion by 2035, Growing at 9.99% CAGR | SNS Insider - GlobeNewswire Inc.
Abbott Laboratories (ABT) Stock After Recent Rebound Is There Still Value Left - Yahoo Finance
Abbott Laboratories' Q2 2026 earnings: What to expect - MSN
Abbott (ABT) Expands In Europe With Instinct CGM And Emerging Market Medicines - simplywall.st
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now? - The Globe and Mail
Abbott Laboratories' Q2 2026 Earnings: What to Expect - Yahoo Finance
Abbott Laboratories sets Q2 earnings date, shares trade firmly on NYSE - Ad-hoc-news.de
Should you buy Abbott Labs stock hand over fist before July 16? - MSN
Abbott shares drop amid sector rotation but growth in diabetes and devices signals buying opportunity. - Pluang
Abbott Laboratories(NYSE: ABT) dropped from Russell Top 50 Index - marketscreener.com
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories Stock (ABT) Moved Up by 3.12% on Jun 25: A Full Analysis - TradingKey
Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy - AOL.com
Price to sales forward of Abbott Laboratories – NYSE:ABT - TradingView
Abbott Laboratories highlights diagnostics growth, shares sit in the S&P 500 health cohort - Ad-hoc-news.de
Price to sales forward of Abbott Laboratories – LSX:850103 - TradingView
$Abbott Laboratories (ABT.US)$ - Moomoo
Abbott to post Q2 results July 16, then host live webcast - Stock Titan
How An ALZpath Alzheimer’s Test Deal And Dividend Streak At Abbott (ABT) Has Changed Its Investment Story - simplywall.st
How Does Wall Street View Abbott Laboratories (ABT)’s Outlook? - Insider Monkey
ALZpath and Abbott Partner to Develop New Blood Test for Alzheimer’s Disease - Clinical Lab Products
Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy - 24/7 Wall St.
Abbott partners with ALZpath on Alzheimer’s blood test - grafa.com
MiniMed Launches Abbott's Instinct Sensors Across European Markets - Yahoo Finance Singapore
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test - Reuters
Abbott (ABT) Partners with ALZpath for Innovative Alzheimer's Di - GuruFocus
Dividend Stocks That Could Hold Up Better If Rates Stay Higher For Longer - simplywall.st
ALZpath licenses Alzheimer’s antibody to Abbott for diagnostic test - Investing.com
ALZpath licenses Alzheimer’s antibody to Abbott for diagnostic test By Investing.com - Investing.com Canada
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):